Cell therapy approaches to autism: a review of clinical trial data

Price, John

doi:10.1186/s13229-020-00348-z

Cited by 15 publications

(15 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on results obtained from animal research, stem cell transplantations have been conducted for children with ASD at several centers 26 . Two distinct approaches have been explored thus far in the application of cell therapy products for the treatment of ASD: culture expanded and nonexpanded.…”

Section: Introductionmentioning

confidence: 99%

“…25 Based on results obtained from animal research, stem cell transplantations have been conducted for children with ASD at several centers. 26 Two distinct approaches have been explored thus far in the application of cell therapy products for the treatment of ASD: culture expanded and nonexpanded. In an early example of non-cultureexpanded cell therapy, Sharma et al described the use of autologous bone marrow mononuclear cell (BMMNC) transplantation infused via intrathecal route in 32 children with ASD.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Outcomes of bone marrow mononuclear cell transplantation combined with interventional education for autism spectrum disorder

Thanh

Nguyen

Ngo

et al. 2020

Stem Cells Translational Medicine

View full text Add to dashboard Cite

The aim of this study was to evaluate the safety and efficacy of autologous bone marrow mononuclear cell transplantation combined with educational intervention for children with autism spectrum disorder. An open-label clinical trial was performed from July 2017 to August 2019 at Vinmec International Hospital, Hanoi, Vietnam. Thirty children who fulfilled the autism criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, and had Childhood Autism Rating Scale (CARS) scores >37 were selected. Bone marrow was harvested by anterior iliac crest puncture under general anesthesia. The volume collected was as follows: 8 mL/kg for patients under 10 kg (80 mL + [body weight in kg − 10] × 7 mL) for patients above 10 kg. Mononuclear cells were isolated with a Ficoll gradient and then infused intrathecally. The same procedure was repeated 6 months later. After the first transplantation, all patients underwent 8 weeks of educational intervention based on the Early Start Denver Model. There were no severe adverse events associated with transplantation. The severity of autism spectrum disorder (ASD) was significantly reduced, with the median CARS score decreasing from 50 (range 40-55.5) to 46.5 (range 33.5-53.5) (P < .05). Adaptive capacity increased, with the median Vineland Adaptive Behavior Scales score rising from 53.5 to 60.5. Social communication, language, and daily skills improved markedly within 18 months after transplantation. Conversely, repetitive behaviors and hyperactivity decreased remarkably. Autologous bone marrow mononuclear cell transplantation in combination with behavioral intervention was safe and well tolerated in children with ASD (Trial registration: ClinicalTrials.gov identifier: NCT03225651).

show abstract

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

Outcomes of bone marrow mononuclear cell transplantation combined with interventional education for autism spectrum disorder

Thanh

Nguyen

Ngo

et al. 2020

Stem Cells Translational Medicine

View full text Add to dashboard Cite

show abstract

“…For example, MSCs have also been shown to be therapeutic for autism and meningitis, etc. [ 188 , 189 ]. An ideal cell type is not only about its therapeutic effects but also about its accessibility and cost and the time to obtain sufficient quantities.…”

Section: Discussionmentioning

confidence: 99%

Cell Therapy for Neurological Disorders: The Perspective of Promising Cells

Liu

Bobrovskaya

Zhou

2021

Biology

View full text Add to dashboard Cite

Neurological disorders are big public health challenges that are afflicting hundreds of millions of people around the world. Although many conventional pharmacological therapies have been tested in patients, their therapeutic efficacies to alleviate their symptoms and slow down the course of the diseases are usually limited. Cell therapy has attracted the interest of many researchers in the last several decades and has brought new hope for treating neurological disorders. Moreover, numerous studies have shown promising results. However, none of the studies has led to a promising therapy for patients with neurological disorders, despite the ongoing and completed clinical trials. There are many factors that may affect the outcome of cell therapy for neurological disorders due to the complexity of the nervous system, especially cell types for transplantation and the specific disease for treatment. This paper provides a review of the various cell types from humans that may be clinically used for neurological disorders, based on their characteristics and current progress in related studies.

show abstract

“…While we were glad to see the Lancet Commission discuss the problem of dangerous pseudotreatments being promoted online, we wish to draw attention to the fact that many have been initially trialled at universities and other research institutions, or promoted by them, including 'packing' 73,74 , holding therapy 75 , secretin 76 , hyperbaric oxygen 77 , fecal transplants 78,79 , oxytocin 80 and injections of stem cells 81 , to name only a few. Clinical trials can be driven by the promise of commercialising a new "solution", and by negative bias and disdain towards autistic people.…”

Section: Addressing Harmful Research and Treatmentsmentioning

confidence: 99%

Autistic perspectives on the future of clinical autism research

Pukki¹,

Bettin²,

Outlaw³

et al. 2022

Preprint

View full text Add to dashboard Cite

There have been widespread expressions of dissatisfaction among autistic people and communities regarding the recommendations of the Lancet Commission on the future of care and clinical research in autism.1 The authors of this article discussed the Commission’s report and some wider issues related to autism research in general as a committee of autistic people, the Global Autistic Task Force on Autism Research, comprising autistic professionals and representatives of organisations run by and for autistic people, focusing on advocacy, service provision, education and participatory research. The Commission has been addressed in an open letter that drew attention to some of the points also discussed in this article.

show abstract

Cell therapy approaches to autism: a review of clinical trial data

Cited by 15 publications

References 35 publications

Outcomes of bone marrow mononuclear cell transplantation combined with interventional education for autism spectrum disorder

Outcomes of bone marrow mononuclear cell transplantation combined with interventional education for autism spectrum disorder

Cell Therapy for Neurological Disorders: The Perspective of Promising Cells

Autistic perspectives on the future of clinical autism research

Contact Info

Product

Resources

About